Myocor is a clinical stage medical device company dedicated to developing and introducing cutting-edge therapeutic products to address mitral valve insufficiency and heart failure. With their proprietary Shape Change Therapy and innovative technologies, Myocor offers minimally invasive solutions to treat disease states caused by geometrically remodeled hearts. The company has successfully completed the development, pre-clinical studies, and early clinical evaluations of new technologies for the treatment of mitral regurgitation and heart failure.

Currently, Myocor's primary focus is on initiating and executing a clinical study in North America to evaluate the effectiveness of the Coapsys System*. This groundbreaking device and therapy have been specifically designed to treat mild to severe mitral valve insufficiency through a closed heart procedure that is less invasive and performed without the need for a heart-lung bypass machine. The Coapsys therapy aims to improve cardiac function and enhance patient outcomes